| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b4a80ac02f1ecd0e698ec665e9b36b6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate |
2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d478d753683c04bf7d1fa0703dc53bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_000628a20c9f1224954eba005fb22f9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe0837c3677053c2b4e414fa3d8a1597
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b8e7ea1e13bf6c05f5fd21c889d640
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1af075db89e374fead9083649921eabf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3441f502086766605aeec8d9d2f227de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9b17c33401551b40e5cbbb5129b79d2 |
| publicationDate |
2016-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160052473-A |
| titleOfInvention |
Pharmaceutical composition comprising Ginkgo biloba extract and matrix of sustained release hydrophilic polymers, and its oral sustained release formulation |
| abstract |
The present invention provides a sustained-release oral preparation comprising a Ginkgo biloba extract and a sustained-release matrix system. The oral sustained-release preparation of Ginkgo biloba extract according to the present invention can control the degree of absorption of the active ingredient in vivo by a controllable release rate. When administered to a human body, it exhibits continuous absorption by delayed release rate while passing through the gastrointestinal tract, (platelet activating factor) inhibitory action and antioxidant activity. Therefore, it is possible to improve the compliance of the patient by taking once a day, and at the same time, a high therapeutic effect can be expected. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018097629-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180127951-A |
| priorityDate |
2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |